studies

la/mBC - HR-positive - 2nd line (L2), tucidinostat based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsACE, 2019 0.75 [0.58; 0.97] 0.75[0.58; 0.97]ACE, 201910%365NAnot evaluable CBRdetailed resultsACE, 2019 1.59 [1.02; 2.49] 1.59[1.02; 2.49]ACE, 201910%365NAnot evaluable DORdetailed resultsACE, 2019 1.43 [0.41; 4.96] 1.43[0.41; 4.96]ACE, 201910%56NAnot evaluable objective responses (ORR)detailed resultsACE, 2019 2.26 [1.12; 4.55] 2.26[1.12; 4.55]ACE, 201910%365NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-02 07:26 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 353,358,359 - treatments: 1365,1366